Resverlogix Corp RFS-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 8:07 AM CEST
0.585quote price arrow up+0.01 (+1.74%)
52 week range
0.34 - 0.89

...

Loading . . .
  • Open0.585
  • Day High0.585
  • Day Low0.585
  • Prev Close0.575
  • 52 Week High0.89
  • 52 Week High Date09/29/20
  • 52 Week Low0.34
  • 52 Week Low Date06/09/20

Key Stats

  • Market Cap167.03M
  • Shares Out234.96M
  • 10 Day Average Volume222.22
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change2.63

KEY STATS

  • Open0.585
  • Day High0.585
  • Day Low0.585
  • Prev Close0.575
  • 52 Week High0.89
  • 52 Week High Date09/29/20
  • 52 Week Low0.34
  • 52 Week Low Date06/09/20
  • Market Cap167.03M
  • Shares Out234.96M
  • 10 Day Average Volume222.22
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change2.63

RATIOS/PROFITABILITY

  • EPS (TTM)0.04
  • P/E (TTM)14.62
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Resverlogix Corp

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of...
Donald McCaffrey
Chairman
A. Brad Cann
Chief Financial Officer
Address
300-4820 Richard Rd SW
Calgary, AB
T3E 6L1
Canada